Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30331.13% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.95M.
Undervalued
The company’s latest PE is -42.80, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.75M shares, decreasing 3.15% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 84.59K shares of this stock.